Literature DB >> 24421482

Perampanel.

Dennis J Cada1, Terri L Levien2, Danial E Baker3.   

Abstract

Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation/medication use evaluation (DUE/MUE) is also provided each month. With a subscription, the monographs are sent in print and are also available on-line. Monographs can be customized to meet the needs of a facility. A drug class review is now published monthly with The Formulary Monograph Service. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. For more information about The Formulary Monograph Service.Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. For more information about The Formulary Monograph Service, call The Formulary at 800-322-4349. The April 2013 monograph topics are alogliptin, crofelemer, lomitapide, ponatinib, and sumatriptan iontophoretic transdermal. The DUE/MUE is on alogliptin.

Entities:  

Year:  2013        PMID： 24421482      PMCID： PMC3839447          DOI： 10.1310/hpj4804-321

Source DB:  PubMed          Journal:  Hosp Pharm        ISSN： 0018-5787


  13 in total

1.  Perampanel: a novel, orally active, noncompetitive AMPA-receptor antagonist that reduces seizure activity in rodent models of epilepsy.

Authors:  Takahisa Hanada; Yutaka Hashizume; Naoki Tokuhara; Osamu Takenaka; Naohiro Kohmura; Aichi Ogasawara; Shinji Hatakeyama; Makoto Ohgoh; Masataka Ueno; Yukio Nishizawa
Journal:  Epilepsia       Date:  2011-06-02       Impact factor: 5.864

2.  Overview of drugs used for epilepsy and seizures: etiology, diagnosis, and treatment.

Authors:  Marvin M Goldenberg
Journal:  P T       Date:  2010-07

3.  Tolerability and safety of perampanel: two randomized dose-escalation studies.

Authors:  G L Krauss; M Bar; V Biton; J A Klapper; I Rektor; N Vaiciene-Magistris; D Squillacote; D Kumar
Journal:  Acta Neurol Scand       Date:  2011-08-29       Impact factor: 3.209

4.  A novel anti-epileptic agent, perampanel, selectively inhibits AMPA receptor-mediated synaptic transmission in the hippocampus.

Authors:  Laura Ceolin; Zuner A Bortolotto; Neil Bannister; Graham L Collingridge; David Lodge; Arturas Volianskis
Journal:  Neurochem Int       Date:  2012-03-10       Impact factor: 3.921

5.  Safety and efficacy of perampanel in advanced Parkinson's disease: a randomized, placebo-controlled study.

Authors:  Karla Eggert; David Squillacote; Paolo Barone; Richard Dodel; Regina Katzenschlager; Murat Emre; Andrew J Lees; Olivier Rascol; Werner Poewe; Eduardo Tolosa; Claudia Trenkwalder; Marco Onofrj; Fabrizio Stocchi; Giuseppe Nappi; Vladimir Kostic; Jagoda Potic; Evzen Ruzicka; Wolfgang Oertel
Journal:  Mov Disord       Date:  2010-05-15       Impact factor: 10.338

6.  Randomized phase III study 306: adjunctive perampanel for refractory partial-onset seizures.

Authors:  G L Krauss; J M Serratosa; V Villanueva; M Endziniene; Z Hong; J French; H Yang; D Squillacote; H B Edwards; J Zhu; A Laurenza
Journal:  Neurology       Date:  2012-04-18       Impact factor: 9.910

7.  Adjunctive perampanel for refractory partial-onset seizures: randomized phase III study 304.

Authors:  Jacqueline A French; Gregory L Krauss; Victor Biton; David Squillacote; Haichen Yang; Antonio Laurenza; Dinesh Kumar; Michael A Rogawski
Journal:  Neurology       Date:  2012-07-25       Impact factor: 9.910

8.  Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: results of randomized global phase III study 305.

Authors:  Jacqueline A French; Gregory L Krauss; Bernhard J Steinhoff; David Squillacote; Haichen Yang; Dinesh Kumar; Antonio Laurenza
Journal:  Epilepsia       Date:  2012-08-20       Impact factor: 5.864

9.  Perampanel Study 207: long-term open-label evaluation in patients with epilepsy.

Authors:  I Rektor; G L Krauss; M Bar; V Biton; J A Klapper; N Vaiciene-Magistris; R Kuba; D Squillacote; M Gee; D Kumar
Journal:  Acta Neurol Scand       Date:  2012-08-23       Impact factor: 3.209

10.  An integrative view of mechanisms underlying generalized spike-and-wave epileptic seizures and its implication on optimal therapeutic treatments.

Authors:  Boyuan Yan; Peng Li
Journal:  PLoS One       Date:  2011-07-21       Impact factor: 3.240
View more
  2 in total

Review 1.  Practice Update: Review of Anticonvulsant Therapy.

Authors:  Derek J Chong; Andrew M Lerman
Journal:  Curr Neurol Neurosci Rep       Date:  2016-04       Impact factor: 5.081

2.  Infection-Induced Elevated Plasma Perampanel in a Patient with Hemimegalencephaly.

Authors:  Yuya Kinoshita; Hiroe Ueno; Hirofumi Kurata; Chizuru Ikeda; Erika Hori; Takumi Okada; Tomoyuki Shimazu; Isao Fujii; Makoto Matsukura; Hoseki Imamura
Journal:  Case Rep Pediatr       Date:  2022-04-29
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.